
ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.
ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.
Your daily dose of the clinical news you may have missed.
This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.
ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.
ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.
Your daily dose of the clinical news you may have missed.
ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.
Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.
For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.
Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.
Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.
Your daily dose of the clinical news you may have missed.
Global prevalence of adults 65 years and older with T1D increased 180% in the past 30 years, researchers reported.
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
Your daily dose of the clinical news you may have missed.
Abbott becomes the second company to receive FDA clearance for an over-the-counter continuous glucose monitoring system.
Your daily dose of the clinical news you may have missed.
There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.
Your daily dose of the clinical news you may have missed.
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.
ENDO 2024. The expert panel suggests children, pregnant persons, adults aged ≥75 years, and adults with prediabetes consume more vitamin D than the recommended daily allowance.